Main Postoperative Complications After SARS-CoV-2 Infection

Overview

To explore the relationship between SARS-CoV-2 infection in different time before operation and postoperative main complications (mortality, main pulmonary and cardiovascular complications) 30 days after operation; To determine the best timing of surgery after SARS-CoV-2 infection.

Full Title of Study: “Main Postoperative Complications After SARS-CoV-2 Infection: A Prospective Cohort Study”

Study Type

• Study Type: Observational
• Study Design
  • Time Perspective: Prospective
• Study Primary Completion Date: February 1, 2024

Clinical Trial Outcome Measures

Primary Measures

• All-cause mortality at 30 days after operation
  • Time Frame: 30 days after surgery
  • All-cause mortality at 30 days after operation

Secondary Measures

• Main pulmonary complications at 30 days after operation
  • Time Frame: 30 days after surgery
  • a composite of postoperative pneumonia, acute respiratory distress syndrome (ARDS) and unexpected ventilation
• Major Adverse Cardiovascular Events (MACE)
  • Time Frame: 30 days after surgery
  • a composite of myocardial infarction, new-onset heart failure or cardiogenic shock, deep vein thrombosis (DVT), pulmonary embolism (PE), and cerebrovascular accident (CVA)

Participating in This Clinical Trial

Inclusion Criteria

• Age≥18 years; – Patients undergoing any type of elective or confine surgery in operating room; – Informed consent. Exclusion Criteria:

• Surgery under local anesthesia (without participation of anesthetist) – Surgery outside the operating room, such as gastrointestinal endoscopy, puncture biopsy, etc – Patients who cannot determine whether they have had SARS CoV-2 infection before surgery – Participating in conflicting clinical study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

• Lead Sponsor
  • RenJi Hospital
• Collaborator
  • The First Affiliated Hospital of Anhui Medical University
• Provider of Information About this Clinical Study
  • Sponsor
• Overall Official(s)
  • Diansan Su, MD,PHD, Study Chair, Renji Hospital, Shanghai Jiaotong University, School of Medcine
• Overall Contact(s)
  • Diansan Su, MD,PHD, +8618616514088, diansansu@yahoo.com